VIRI Virios Therapeutics
- 0.410
- +0.004+0.86%
Virios Therapeutics News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 d
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript
Maintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development Risks
Earnings Call Summary | Virios Therapeutics(VIRI.US) Q1 2024 Earnings Conference
The following is a summary of the Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript:Financial Performance:Virios Therapeutics reported a decrease in research and development expenses,
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
Virios Therapeutics | 10-Q: Quarterly report
Virios Therapeutics Q1 2024 GAAP EPS $(0.07) Misses $(0.04) Estimate
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.04) by 75 percent. This is a 12.5 percent increase over losses of $(
Virios Therapeutics Believes It Will Have Sufficient Resources to Fund Ops Into the 4Q of 2024 >VIRI
Virios Therapeutics Believes It Will Have Sufficient Resources to Fund Ops Into the 4Q of 2024 >VIRI
Virios Therapeutics 1Q Loss $1.29M >VIRI
Virios Therapeutics 1Q Loss $1.29M >VIRI
Virios Therapeutics 1Q Loss/Shr 7c >VIRI
Virios Therapeutics 1Q Loss/Shr 7c >VIRI
Virios Therapeutics Continues to Actively Explore Complementary Opportunities That Will Build Shareholder Value Through Strategic Partnerships, Collaborations or Other Transactions >VIRI
Virios Therapeutics Continues to Actively Explore Complementary Opportunities That Will Build Shareholder Value Through Strategic Partnerships, Collaborations or Other Transactions >VIRI
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - -
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
Virios Therapeutics: A Hold Rating With a New Price Target Amidst Clinical and Financial Challenges
Virios Therapeutics Reports Q4 Results
Virios Therapeutics Q4 2023 GAAP EPS $(0.06) Beats $(0.09) Estimate
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent.
Virios Therapeutics: Discussions Ongoing With Potential Partners to Fund Advancement of IMC-1 Into Phase 3 Development for FM >VIRI
Virios Therapeutics: Discussions Ongoing With Potential Partners to Fund Advancement of IMC-1 Into Phase 3 Development for FM >VIRI
Press Release: Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-st
Virios Therapeutics 4Q Loss $1.1M >VIRI
Virios Therapeutics 4Q Loss $1.1M >VIRI
Analysis
Price Target
No Data
